Biotech Funding Rebounds After Regulatory Easing in US and EU
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Global biotech funding rebounded sharply in Q2 2025, driven by a wave of regulatory reforms in the United States and European Union aimed at accelerating drug approval timelines and reducing clinical trial bottlenecks.… Continue reading Biotech Funding Rebounds After Regulatory Easing in US and EU


